Zacks Research Comments on Esperion Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Investment analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a report issued on Tuesday, October 1st. Zacks Research analyst K. Das now expects that the biopharmaceutical company will earn ($0.15) per share for the quarter, down from their previous forecast of ($0.13). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.04) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at $0.16 EPS, Q4 2025 earnings at $0.25 EPS, FY2025 earnings at $0.14 EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at $0.15 EPS and FY2026 earnings at $0.07 EPS.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.10. The firm had revenue of $73.83 million for the quarter, compared to the consensus estimate of $51.90 million.

ESPR has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Wednesday. Needham & Company LLC cut their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. StockNews.com upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Bank of America lowered Esperion Therapeutics from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $2.90 to $2.50 in a research note on Thursday, June 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Esperion Therapeutics presently has a consensus rating of “Hold” and an average price target of $8.17.

Esperion Therapeutics Stock Performance

Shares of Esperion Therapeutics stock opened at $2.16 on Friday. Esperion Therapeutics has a one year low of $0.70 and a one year high of $3.40. The stock’s fifty day moving average is $1.84 and its 200 day moving average is $2.20. The stock has a market cap of $409.23 million, a P/E ratio of -2.18 and a beta of 1.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Capital Advisors Wealth Management LLC lifted its stake in Esperion Therapeutics by 22.9% in the second quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 5,000 shares during the last quarter. Summit Financial LLC raised its stake in Esperion Therapeutics by 26.4% in the second quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 6,823 shares in the last quarter. National Bank of Canada FI raised its stake in Esperion Therapeutics by 115.9% in the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 10,225 shares in the last quarter. GSA Capital Partners LLP raised its stake in Esperion Therapeutics by 1.0% in the fourth quarter. GSA Capital Partners LLP now owns 1,128,149 shares of the biopharmaceutical company’s stock worth $3,373,000 after buying an additional 11,494 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in Esperion Therapeutics by 45.3% in the second quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 11,658 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.